Michael Thurn
Director/Board Member bei Marp Therapeutics Pty Ltd.
Profil
Michael Thurn is currently a Director at Marp Therapeutics Pty Ltd., Inmagene Biopharmaceuticals, and Impel Neuropharma.
Previously, he served as the Chief Executive Officer of Mimetica Pty Ltd.
from 2006 to 2014.
He also held the position of Chief Executive Officer at PharmAust Ltd.
in 2023 and 2024.
Additionally, he was the Chief Operating Officer & Executive Director at Botanix Pharmaceuticals Ltd.
from 2019 to 2020.
Dr. Thurn has also worked as the Managing Director at Spinifex Pharmaceuticals Pty Ltd., Director at Erasca, Inc., Team Leader at Kazia Therapeutics Ltd., Chief Operating Officer at YM BioSciences Australia Pty Ltd., Head-Drug Development at Xenome Ltd., and Senior Toxicologist at Therapeutic Goods Administration.
He obtained his doctorate degree from the University of Technology Sydney in 1994.
Aktive Positionen von Michael Thurn
Unternehmen | Position | Beginn |
---|---|---|
Marp Therapeutics Pty Ltd.
Marp Therapeutics Pty Ltd. Medical/Nursing ServicesHealth Services Marp Therapeutics Pty Ltd. provides therapy services. The company is based in Melbourne, Australia. | Director/Board Member | - |
Ehemalige bekannte Positionen von Michael Thurn
Unternehmen | Position | Ende |
---|---|---|
PHARMAUST LIMITED | Chief Executive Officer | 23.04.2024 |
BOTANIX PHARMACEUTICALS LIMITED | Chief Operating Officer | 26.02.2020 |
ERASCA, INC. | Director/Board Member | - |
Therapeutic Goods Administration | Corporate Officer/Principal | - |
KAZIA THERAPEUTICS LIMITED | Corporate Officer/Principal | - |
Ausbildung von Michael Thurn
University of Technology Sydney | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
KAZIA THERAPEUTICS LIMITED | Health Technology |
BOTANIX PHARMACEUTICALS LIMITED | Health Technology |
PHARMAUST LIMITED | Health Technology |
ERASCA, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
YM BioSciences Australia Pty Ltd.
YM BioSciences Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., YM BioSciences Australia Pty Ltd. develops cancer treatment pharmaceuticals. The private company is based in Melbourne, Australia. | Health Technology |
Xenome Ltd.
Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Health Technology |
Mimetica Pty Ltd.
Mimetica Pty Ltd. Pharmaceuticals: MajorHealth Technology Mimetica Pty Ltd. is a holding company, which engages in the development of products for the treatment of acne. It has a drug discovery platform technology based on the rational design of small molecules that mimic natural peptide hormones. The company was founded in 2001 and is headquartered in Southbank, Australia. | Health Technology |
Spinifex Pharmaceuticals Pty Ltd.
Spinifex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology Spinifex Pharmaceuticals Pty Ltd. discovers and develops new drugs for the treatment and management of pain. The firm conducts medicinal chemistry and drug discovery activities, preclinical and early-phase clinical studies before seeking a partnership with pharmaceutical company to complete clinical development, file for regulatory approval, and carry out marketing activities. The company was founded in June 2005 and is headquartered in Preston, Australia. | Health Technology |
Therapeutic Goods Administration | |
Marp Therapeutics Pty Ltd.
Marp Therapeutics Pty Ltd. Medical/Nursing ServicesHealth Services Marp Therapeutics Pty Ltd. provides therapy services. The company is based in Melbourne, Australia. | Health Services |